ArticleSubstance abuse2021
It will end in tiers: A strategy to include "dabblers" in the buprenorphine workforce after the X-waiver.
Article in Substance abuse, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Advancing Pharmacological Treatments for Opioid Use Disorder (ADaPT-OUD): an Implementation Trial in Eight Veterans Health Administration Facilities.Journal of general internal medicine · 2022Trial
- Assessing the Initial Impact of X-Waiver Elimination on Buprenorphine Prescribing for Opioid Use Disorder.Substance use & addiction journal · 2026Article
- High-volume buprenorphine prescribers: Examining state policy contexts.Drug and alcohol dependence reports · 2026Article
- A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.BMC health services research · 2024Article
- Navigating addiction treatment during COVID-19: policy insights from state health leaders.Health affairs scholar · 2024Article
- "Because of this rotation, this is what I want to do": Implementation and evaluation of a telehealth opioid use disorder clinical placement for nurse practitioner students.Journal of the American Association of Nurse Practitioners · 2023Article
- Internal and Environmental Predictors of Physician Practice Use of Screening and Medications for Opioid Use Disorders.Medical care research and review : MCRR · 2023Article
- Exploring the Association of State Policies and the Trajectories of Buprenorphine Prescriber Patient Caseloads.Substance abuse · 2023Article
- Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act.Substance abuse · 2023Article
- Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.Journal of general internal medicine · 2023Article
- Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.JAMA health forum · 2023Article
- Estimated Clinical Outcomes and Cost-effectiveness Associated With Provision of Addiction Treatment in US Primary Care Clinics.JAMA network open · 2023Article
- The Future of the United States Overdose Crisis: Challenges and Opportunities.The Milbank quarterly · 2023Article
- Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.Drug and alcohol dependence · 2022Article
- Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".The International journal on drug policy · 2022Article
- Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.Addiction science & clinical practice · 2022Article
- Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.Journal of substance abuse treatment · 2022Article
- Subsequent Buprenorphine Treatment Following Emergency Physician Buprenorphine Prescription Fills: A National Assessment 2019 to 2020.Annals of emergency medicine · 2022Observational
- How Physician Workforce Shortages Are Hampering the Response to the Opioid Crisis.Psychiatric services (Washington, D.C.) · 2022Article
- Patient Perspectives on Opioid Risk Discussions in Primary Care.Journal of patient-centered research and reviews · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Buprenorphine is one of the gold standard medication treatments for opioid use disorder (OUD), with proven effectiveness in preventing overdose, increasing abstinence, and improving quality of life. In the United States, buprenorphine can be legally prescribed and administered in office-based settings from clinicians who are specially credentialed to provide that care under the X-waiver. We believe the X-waiver will ultimately be repealed, but there is a need for a variety of strategies to create a new treatment system after the X-waiver. Building a new tier of treatment capacity will require educational outreach, systems strategies, and enhanced payments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.